Mode
Text Size
Log in / Sign up
Phase 1 N=12 Treatment

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Human Immunodeficiency Virus (HIV) Infection

Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcome: Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL) — 14.4; 6.54 hr*μM

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Islatravir (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Merck Sharp & Dohme LLC
Primary completion
Oct 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Plasma Islatravir (ISL)
14.4; 6.54
PRIMARY
Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of Plasma ISL
11.0; 5.68
PRIMARY
Maximum Concentration (Cmax) of Plasma ISL
1.23; 1.19
PRIMARY
Time of Maximum Concentration (Tmax) of Plasma ISL
1.03; 0.75
PRIMARY
Apparent Terminal Half-life (t1/2) of Plasma ISL
127; 72.0
PRIMARY
Apparent Clearance (CL/F) of Plasma ISL
14.2; 31.3
PRIMARY
Apparent Volume of Distribution (Vz/F) of Plasma ISL
2610; 3250
SECONDARY
AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)
5810; 3920
SECONDARY
AUC0-last of ISL-TP in PBMC
5200; 3780
SECONDARY
Cmax of ISL-TP in PBMC
20.3; 21.6
SECONDARY
Tmax of ISL-TP in PBMC
36.00; 24.00
SECONDARY
Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC
18.4; 19.0
SECONDARY
Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC
8.06; 4.43
SECONDARY
Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC
1.96; 0.730
SECONDARY
T1/2 of ISL-TP in PBMC
181; 131
SECONDARY
Percentage of Participants With an Adverse Event (AE)
16.7; 0.0
SECONDARY
Percentage of Participants Who Discontinued From the Study Due to an AE
0.0; 0.0

Summary

This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg dose of MK-8591 (Islatravir) in participants with severe renal insufficiency, compared to participants in good health.

Eligibility Criteria

Inclusion Criteria

Healthy participants must have the following:

  • Is in good health
  • Has a body mass index (BMI) ≥18.5 and ≤40 kg/m2.
  • Female is not pregnant or breastfeeding, and is not one of the following: a woman of childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive method, or is abstinent from heterosexual intercourse as their preferred and usual lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention

Renally impaired participants must have the following:

  • With the exception of renal impairment, is in generally good health
  • Has a BMI ≥ 18.5 and ≤ 40 kg/m2
  • Female is not pregnant or breastfeeding, and is not one of the following: a woman of childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive method, or is abstinent from heterosexual intercourse as their preferred and usual lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention

Exclusion Criteria

Healthy participants must have the following:

  • Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Is mentally or legally incapacitated, has significant emotional problems
  • Has known hypersensitivity to the active substance or any of the excipients of the study drug
  • Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.
  • Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within prior 4 weeks
  • Is taking medications to treat chronic medical conditions and/or conditions associated with renal disease
  • Has participated in another investigational study within prior 4 weeks

Other exclusions for healthy participants:

  • Does not agree to follow the smoking restrictions
  • Consumes greater than 1 glass for women, or 2 glasses for men of alcoholic beverages per day
  • Consumes excessive amounts, of caffeinated beverages per day.
  • Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately prior 3 months.

Renally impaired participants must have the following:

  • Has a history or presence of renal artery stenosis.
  • Has had a renal transplant or nephrectomy.
  • Has rapidly fluctuating renal function as determined by historical measurements.
  • Has known hypersensitivity to the active substance or any of the excipients of the study drug.
  • Has a history of cancer (malignancy).
  • Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.
  • Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV).
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
  • Is taking medications to treat chronic medical conditions and/or conditions associated with renal disease and has not been on a stable regimen for at least 1 month and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 8 hours after administration of the study drug.
  • Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit.

Other exclusions for renally impaired participants

  • Does not agree to follow the smoking restrictions.
  • Consumes greater than 1
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04303156). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search